Trials / Unknown
UnknownNCT04450030
Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis
Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of Action
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 204 (estimated)
- Sponsor
- University Hospital Muenster · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Treatment of acute relapsing multiple sclerosis (MS) has remained largely unaltered within past years. However, evidence defining the exact role of apheresis treatment in the therapeutic sequence is still incomplete. INCIDENT-MS evaluates the mechanism of action of immunoadsorption compared to escalated methyl prednisolone treatment in steroid-refractory MS relapses and thereby will help to identify predictive markers for optimal treatment choice and will generate further insights into the pathophysiology of MS relapses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methyl Prednisolonate | 2000mg intravenous methyl prednisolone per day for five consecutive days |
| PROCEDURE | Immunoadsorption | 6 courses of tryptophane-based immunoadsorption within up to 12 days |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2020-09-05
- Completion
- 2020-12-31
- First posted
- 2020-06-29
- Last updated
- 2020-11-12
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04450030. Inclusion in this directory is not an endorsement.